MBX Key Statistics, Chart & Performance
The current stock price of MBX is 31.9 USD. In the past month the price increased by 35.43%. In the past year, price increased by 37.69%.
MBX Latest News, Press Relases and Analysis
MBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.81 | 952.31B | ||
| JNJ | JOHNSON & JOHNSON | 19.44 | 486.28B | ||
| MRK | MERCK & CO. INC. | 11.34 | 247.99B | ||
| PFE | PFIZER INC | 8.16 | 148.40B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.94 | 106.07B | ||
| ZTS | ZOETIS INC | 18.73 | 52.32B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.60B | ||
| VTRS | VIATRIS INC | 4.7 | 12.60B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.71 | 10.83B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.56 | 9.03B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.55B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.28B |
Related stock screener links
About MBX
Company Profile
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana and currently employs 43 full-time employees. The company went IPO on 2024-09-13. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
Company Info
MBX BIOSCIENCES INC
11711 N. Meridian Street, Suite 300
Carmel INDIANA US
Employees: 43
Phone: 13179893100
MBX BIOSCIENCES INC / MBX FAQ
What does MBX BIOSCIENCES INC do?
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana and currently employs 43 full-time employees. The company went IPO on 2024-09-13. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
Can you provide the latest stock price for MBX BIOSCIENCES INC?
The current stock price of MBX is 31.9 USD. The price increased by 4.45% in the last trading session.
Does MBX stock pay dividends?
MBX does not pay a dividend.
How is the ChartMill rating for MBX BIOSCIENCES INC?
MBX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of MBX BIOSCIENCES INC (MBX) based on its PE ratio?
MBX BIOSCIENCES INC (MBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).
Can you provide the upcoming earnings date for MBX BIOSCIENCES INC?
MBX BIOSCIENCES INC (MBX) will report earnings on 2026-03-17.
Who owns MBX BIOSCIENCES INC?
You can find the ownership structure of MBX BIOSCIENCES INC (MBX) on the Ownership tab.
MBX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MBX. When comparing the yearly performance of all stocks, MBX is one of the better performing stocks in the market, outperforming 96.9% of all stocks.
MBX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MBX. No worries on liquidiy or solvency for MBX as it has an excellent financial health rating, but there are worries on the profitability.
MBX Financial Highlights
Over the last trailing twelve months MBX reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -38.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.12% | ||
| ROE | -20.77% | ||
| Debt/Equity | 0 |
MBX Forecast & Estimates
12 analysts have analysed MBX and the average price target is 61.33 USD. This implies a price increase of 92.25% is expected in the next year compared to the current price of 31.9.